Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (Lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)

newsfileJan 13 08:00 ET

European Equities Traded in the US as American Depositary Move Slightly Lower in Thursday Trading

MT NewswiresDec 19, 2024 11:08 ET

Adaptimmune Says CFO, Other C-Suite Officer to Step Down

WSJDec 19, 2024 08:23 ET

Adaptimmune: Focusing Increasing Proportion of Corporate Functions in U.S. >ADAP

Dow JonesDec 19, 2024 07:48 ET

Adaptimmune: Co-Founder, Chief Business & Strategy Officer Helen Tayton-Martin to Step Down on March 31 >ADAP

Dow JonesDec 19, 2024 07:47 ET

Express News | Adaptimmune Therapeutics PLC - Gavin Wood to Step Down as Chief Financial Officer

ReutersDec 19, 2024 07:41 ET